Hokuriku Pharmaceutical rose more than 10%, while many stocks such as Guangshengtang, Yuekang Pharmaceutical, Wanbang Pharmaceutical, Jinshi Asia Pharmaceutical, Boji Pharmaceuticals, and Shutaishen rose more than 5%. According to the news, the State Drug Administration organized and drafted the “Notice on Matters Relating to Optimizing the Evaluation and Approval of Clinical Trials of Innovative Drugs”, which mentions that in order to further support clinical value-oriented innovative drug research and development and improve the quality and efficiency of clinical research and development, clinical trial applications for innovative drugs that meet the requirements will be reviewed and approved within 30 working days.

Zhitongcaijing · 06/17 01:49
Hokuriku Pharmaceutical rose more than 10%, while many stocks such as Guangshengtang, Yuekang Pharmaceutical, Wanbang Pharmaceutical, Jinshi Asia Pharmaceutical, Boji Pharmaceuticals, and Shutaishen rose more than 5%. According to the news, the State Drug Administration organized and drafted the “Notice on Matters Relating to Optimizing the Evaluation and Approval of Clinical Trials of Innovative Drugs”, which mentions that in order to further support clinical value-oriented innovative drug research and development and improve the quality and efficiency of clinical research and development, clinical trial applications for innovative drugs that meet the requirements will be reviewed and approved within 30 working days.